| Nov 14 |
Earnings Scheduled For November 14, 2024
|
| Nov 7 |
Aspira Women’s Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch®
|
| Oct 15 |
Aspira Women’s Health Receives Approval from New York State Department of Health for OvaWatch®
|
| Sep 10 |
Aspira Women’s Health Announces Publication of Data Demonstrating Performance of its In-Development Blood Test for the Assessment of Malignancy Risk in Patients with an Adnexal Mass
|
| Sep 6 |
Aspira Women’s Health to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Sep 5 |
Aspira Women’s Health Selected as a Spoke for the Investor Catalyst Hub
|
| Aug 27 |
Aspira Women’s Health Partners with Dorsata to Create New Clinical Workflow Tool for Adnexal Masses
|
| Aug 14 |
Aspira Women's Health Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Aug 5 |
Aspira Women’s Health’s Announces a Poster Presentation at the 27th Annual National Association of Nurse Practitioners in Women’s Health (NPWH) Women’s Healthcare Conference
|
| Jul 29 |
Aspira Women’s Health Appoints Mr. John Ragard to its Board of Directors
|
